Cartesian Therapeutics, Inc. (RNAC)Healthcare | Biotechnology | Frederick, United States | NasdaqGM
7.04 USD
+0.66
(10.345%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.04 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:49 p.m. EDT
RNAC is a high-risk, speculative stock with a negative forward PE and trailing EPS, indicating poor earnings performance. The stock has been volatile in the short term, with recent price dips and rebounds. While there is some analyst optimism and insider buying, the lack of dividends and weak fundamentals make it a risky investment. Short-term traders may consider buying calls if there is a momentum shift, but long-term investors should be cautious due to the lack of sustainable growth and consistent dividends. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.118556 |
| AutoETS | 0.120919 |
| AutoTheta | 0.121152 |
| MSTL | 0.123495 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 3.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.066 |
| Excess Kurtosis | -0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.108 |
| Market Cap | 186,623,520 |
| Forward P/E | -4.17 |
| Beta | 0.56 |
| Website | https://www.cartesiantherapeutics.com |
As of April 11, 2026, 3:49 p.m. EDT: Options activity suggests mixed sentiment. Calls show significant positioning in the $5.0 strike (ATM) with high open interest and volume, indicating potential support or a buying opportunity. However, puts also show high open interest in the $2.5 strike, suggesting some bearish sentiment. The high IV in some expirations may indicate increased volatility or uncertainty about the stock's direction. Overall, options speculators are signaling a cautious approach, with a focus on potential support levels and possible short-term price movements.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31914896 |
| Address1 | 7,495 New Horizon Way |
| All Time High | 840.0 |
| All Time Low | 5.6 |
| Ask | 7.13 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 211,610 |
| Average Daily Volume3 Month | 189,185 |
| Average Volume | 189,185 |
| Average Volume10Days | 211,610 |
| Beta | 0.558 |
| Bid | 7.0 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -4.853 |
| City | Frederick |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.04 |
| Current Ratio | 8.655 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.2397 |
| Day Low | 6.54 |
| Display Name | Cartesian Therapeutics |
| Earnings Timestamp | 1,773,059,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -83,746,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.886 |
| Enterprise To Revenue | 26.514 |
| Enterprise Value | 74,160,528 |
| Eps Current Year | -2.15 |
| Eps Forward | -1.69 |
| Eps Trailing Twelve Months | -5.02 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.8168 |
| Fifty Day Average Change | 0.22319984 |
| Fifty Day Average Change Percent | 0.032742612 |
| Fifty Two Week Change Percent | -31.914896 |
| Fifty Two Week High | 15.57 |
| Fifty Two Week High Change | -8.53 |
| Fifty Two Week High Change Percent | -0.5478484 |
| Fifty Two Week Low | 5.6 |
| Fifty Two Week Low Change | 1.44 |
| Fifty Two Week Low Change Percent | 0.25714287 |
| Fifty Two Week Range | 5.6 - 15.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,466,602,200,000 |
| Float Shares | 6,835,882 |
| Forward Eps | -1.69 |
| Forward P E | -4.1656804 |
| Free Cashflow | -55,624,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -55,237,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.5959 |
| Held Percent Institutions | 0.28 |
| Implied Shares Outstanding | 26,509,024 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,275,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland. |
| Long Name | Cartesian Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 186,623,520 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_371375105 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -130,302,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 186,888,619 |
| Number Of Analyst Opinions | 7 |
| Open | 6.54 |
| Operating Cashflow | -73,941,000 |
| Operating Margins | -23.166842 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 301 348 8698 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.04 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 6.38 |
| Price Eps Current Year | -3.2744184 |
| Price Hint | 2 |
| Price To Book | -1.450649 |
| Price To Sales Trailing12 Months | 66.72275 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.452 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.66 |
| Regular Market Change Percent | 10.3448 |
| Regular Market Day High | 7.2397 |
| Regular Market Day Low | 6.54 |
| Regular Market Day Range | 6.54 - 7.2397 |
| Regular Market Open | 6.54 |
| Regular Market Previous Close | 6.38 |
| Regular Market Price | 7.04 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 373,253 |
| Return On Assets | -0.14818 |
| Revenue Per Share | 0.108 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 26,509,024 |
| Shares Percent Shares Out | 0.08189999 |
| Shares Short | 2,170,494 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,148,586 |
| Short Name | Cartesian Therapeutics, Inc. |
| Short Percent Of Float | 0.1999 |
| Short Ratio | 7.64 |
| Source Interval | 15 |
| State | MD |
| Symbol | RNAC |
| Target High Price | 44.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 35.57143 |
| Target Median Price | 39.0 |
| Total Cash | 125,139,000 |
| Total Cash Per Share | 4.721 |
| Total Debt | 12,676,000 |
| Total Revenue | 2,797,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.02 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.67825 |
| Two Hundred Day Average Change | -1.6382504 |
| Two Hundred Day Average Change Percent | -0.18877657 |
| Type Disp | Equity |
| Volume | 373,253 |
| Website | https://www.cartesiantherapeutics.com |
| Zip | 21,703 |